Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
58,728.58 +835.09 (+1.44%) CMC Crypto 200
1,265.98 -4.76 (-0.37%)
INCY Nov 2024 40.000 call
| Previous close | 13.60 |
| Open | 13.60 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 40.00 |
| Expiry date | 2024-11-15 |
| Day's range | 13.60 - 13.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
Insider MonkeyIncyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript April 30, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88. INCY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to Incyte First […]
ZacksIncyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
- Reuters
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade. During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG.
